RVL Pharmaceuticals PLC (OTCPK:RVLPQ)
$ 0.0001 0 (0%) Market Cap: 11,000.00 Enterprise Value: 39.00 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Osmotica Pharmaceuticals plc - Special Call Transcript

May 07, 2019 / 04:00PM GMT
Release Date Price: $3.84 (-1.03%)
Operator

Good day, ladies and gentlemen, and welcome to Osmotica RVL update conference call. (Operator Instructions) As a reminder, this conference may be recorded. I would now like to introduce your host for today's conference, Ilanit Allen of Investor Relations. Please begin.

Ilanit Allen

Thank you, Norma. Welcome to Osmotica Pharmaceuticals RVL update call. This is Ilanit Allen, Investor Relations for Osmotica.

With me on today's call are Brian Markison, Chief Executive Officer; JD Schaub, Chief Operating Officer; Tina deVries, Executive Vice President of Research and Development; and David Jacobs, Vice President of Clinical Development, along with key opinion leaders, Dr. Chuck Slonim and Dr. Shane Kannarr.

Yesterday afternoon, the company issued a press release regarding results of the company's Phase III clinical trials of RVL-1201 for acquired blepharoptosis. This press release and webcast of this call and slides for today's program can be accessed through the Investors section of the Osmotica website at osmotica.com. Participants will be able to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot